Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce

A H Musters; L A A Gerbens; L van der Gang; M A Middelkamp-Hup; W Ouwerkerk; D J Hijnen; E Haufe; L Heinrich; T Werfel; S Weidinger; J Schmitt; A Svedbom; E K Johansson; M Bradley; L B von Kobyletzki; I Vittrup; I F Ruge; J P Thyssen; C Vestergaard; J M Carrascosa; M de Vega; I García-Doval; A Chiricozzi; L Stingeni; P Calzavara-Pinton; M R Ardern-Jones; N J Reynolds; C Flohr; P I Spuls

doi:10.1111/jdv.20876

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce

A H Musters
, L A A Gerbens
, L van der Gang
, M A Middelkamp-Hup
, W Ouwerkerk
, D J Hijnen
, E Haufe
, L Heinrich
, T Werfel
, S Weidinger
, J Schmitt
, A Svedbom
, E K Johansson
, M Bradley
, L B von Kobyletzki
, I Vittrup
, I F Ruge
, J P Thyssen
, C Vestergaard
, J M Carrascosa

M de Vega, I García-Doval, A Chiricozzi, L Stingeni, P Calzavara-Pinton, M R Ardern-Jones, N J Reynolds, C Flohr, P I Spuls,

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).

OBJECTIVES: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.

METHODS: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).

RESULTS: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.

CONCLUSIONS: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.

Original language	English
Pages (from-to)	2096-2112
Number of pages	17
Journal	JEADV : journal of the European Academy of Dermatology and Venereology
Volume	39
Issue number	12
Early online date	20 Aug 2025
DOIs	https://doi.org/10.1111/jdv.20876
Publication status	Published - Dec 2025

Keywords

atopic dermatitis
atopic eczema
baseline
demographics
disease burden
disease severity
patient-reported outcomes
phototherapy
real-world data
registry
systemic immunomodulating treatment

Access to Document

10.1111/jdv.20876Licence: CC BY-NC-ND

Acad Dermatol Venereol - 2025 - Musters - Baseline characteristics of atopic eczema patients enrolled in seven EuropeanFinal published version, 532 KBLicence: CC BY-NC-ND

Cite this

Musters, A. H., Gerbens, L. A. A., van der Gang, L., Middelkamp-Hup, M. A., Ouwerkerk, W., Hijnen, D. J., Haufe, E., Heinrich, L., Werfel, T., Weidinger, S., Schmitt, J., Svedbom, A., Johansson, E. K., Bradley, M., von Kobyletzki, L. B., Vittrup, I., Ruge, I. F., Thyssen, J. P., Vestergaard, C. (2025). Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce. JEADV : journal of the European Academy of Dermatology and Venereology, 39(12), 2096-2112. https://doi.org/10.1111/jdv.20876

@article{c41856e4ab474377b9c756e0cfaed45a,

title = "Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce",

abstract = "BACKGROUND: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).OBJECTIVES: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.METHODS: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).RESULTS: The analysis included 5337 patients, with a mean age of 39.1 years (6.3\% paediatric, 54.4\% male). Of these, 84.1\% had previously received systemic treatments, primarily systemic corticosteroids (58.8\%) and ciclosporin (39.0\%), while 30.1\% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0\%), followed by ciclosporin (7.8\%) and Janus Kinase inhibitors (5.9\%); only 1.7\% started phototherapy. Baseline assessments showed that most patients had moderate (41.9\%) to severe (30.1\%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.CONCLUSIONS: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.",

keywords = "atopic dermatitis, atopic eczema, baseline, demographics, disease burden, disease severity, patient-reported outcomes, phototherapy, real-world data, registry, systemic immunomodulating treatment",

author = "Musters, \{A H\} and Gerbens, \{L A A\} and \{van der Gang\}, L and Middelkamp-Hup, \{M A\} and W Ouwerkerk and Hijnen, \{D J\} and E Haufe and L Heinrich and T Werfel and S Weidinger and J Schmitt and A Svedbom and Johansson, \{E K\} and M Bradley and \{von Kobyletzki\}, \{L B\} and I Vittrup and Ruge, \{I F\} and Thyssen, \{J P\} and C Vestergaard and Carrascosa, \{J M\} and \{de Vega\}, M and I Garc{\'i}a-Doval and A Chiricozzi and L Stingeni and P Calzavara-Pinton and Ardern-Jones, \{M R\} and Reynolds, \{N J\} and C Flohr and Spuls, \{P I\}",

note = "Publisher Copyright: {\textcopyright} 2025 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley \& Sons Ltd on behalf of European Academy of Dermatology and Venereology.",

year = "2025",

month = dec,

doi = "10.1111/jdv.20876",

language = "English",

volume = "39",

pages = "2096--2112",

journal = "JEADV : journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley \& Sons Inc.",

number = "12",

}

Musters, AH, Gerbens, LAA, van der Gang, L, Middelkamp-Hup, MA, Ouwerkerk, W, Hijnen, DJ, Haufe, E, Heinrich, L, Werfel, T, Weidinger, S, Schmitt, J, Svedbom, A, Johansson, EK, Bradley, M, von Kobyletzki, LB, Vittrup, I, Ruge, IF, Thyssen, JP, Vestergaard, C, Carrascosa, JM, de Vega, M, García-Doval, I, Chiricozzi, A, Stingeni, L, Calzavara-Pinton, P, Ardern-Jones, MR, Reynolds, NJ, Flohr, C, Spuls, PI 2025, 'Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce', JEADV : journal of the European Academy of Dermatology and Venereology, vol. 39, no. 12, pp. 2096-2112. https://doi.org/10.1111/jdv.20876

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce. / Musters, A H; Gerbens, L A A; van der Gang, L et al.
In: JEADV : journal of the European Academy of Dermatology and Venereology, Vol. 39, No. 12, 12.2025, p. 2096-2112.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce

AU - Musters, A H

AU - Gerbens, L A A

AU - van der Gang, L

AU - Middelkamp-Hup, M A

AU - Ouwerkerk, W

AU - Hijnen, D J

AU - Haufe, E

AU - Heinrich, L

AU - Werfel, T

AU - Weidinger, S

AU - Schmitt, J

AU - Svedbom, A

AU - Johansson, E K

AU - Bradley, M

AU - von Kobyletzki, L B

AU - Vittrup, I

AU - Ruge, I F

AU - Thyssen, J P

AU - Vestergaard, C

AU - Carrascosa, J M

AU - de Vega, M

AU - García-Doval, I

AU - Chiricozzi, A

AU - Stingeni, L

AU - Calzavara-Pinton, P

AU - Ardern-Jones, M R

AU - Reynolds, N J

AU - Flohr, C

AU - Spuls, P I

N1 - Publisher Copyright: © 2025 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2025/12

Y1 - 2025/12

N2 - BACKGROUND: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).OBJECTIVES: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.METHODS: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).RESULTS: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.CONCLUSIONS: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.

AB - BACKGROUND: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE).OBJECTIVES: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe.METHODS: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium).RESULTS: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4.CONCLUSIONS: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.

KW - atopic dermatitis

KW - atopic eczema

KW - baseline

KW - demographics

KW - disease burden

KW - disease severity

KW - patient-reported outcomes

KW - phototherapy

KW - real-world data

KW - registry

KW - systemic immunomodulating treatment

UR - https://www.scopus.com/pages/publications/105013855252

U2 - 10.1111/jdv.20876

DO - 10.1111/jdv.20876

M3 - Article

C2 - 40832875

SN - 0926-9959

VL - 39

SP - 2096

EP - 2112

JO - JEADV : journal of the European Academy of Dermatology and Venereology

JF - JEADV : journal of the European Academy of Dermatology and Venereology

IS - 12

ER -

Musters AH, Gerbens LAA, van der Gang L, Middelkamp-Hup MA, Ouwerkerk W, Hijnen DJ et al. Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce. JEADV : journal of the European Academy of Dermatology and Venereology. 2025 Dec;39(12):2096-2112. Epub 2025 Aug 20. doi: 10.1111/jdv.20876

Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this